Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/3248777

Documents

In Collections

This item can be found in the following collections:

Brandt, R.B.; Doesborg, P.G.G.; Meilof, R.; Coo, I.F. de; Bartels, E.; Ferrari, M.D.; Fronczek, R. (2021)

Repeated greater occipital nerve injections with corticosteroids in medically intractable chronic cluster headache: a retrospective study

Article / Letter to editor
Introduction Current prophylactic drugs for cluster headache are associated with limited efficacy, serious side effects and poor tolerability. Greater occipital nerve injection (GON-injection) has been proven effective and safe as a single, one-time injection in episodic (ECH), and to a lesser extent, chronic cluster headache (CCH). We aim to analyse the effectiveness and safety of repeated GON-injections in medically intractable chronic cluster headache (MICCH). Methods Clinical data of all cluster headache patients who had received at least one GON-injection between 2014 and 2018 in our tertiary headache centre were retrieved from patients' medical records. Clinical history was taken as part of routine care shortly before and 6 weeks after GON-injection. Results We identified 47 MICCH patients (79 injections), and compared results with 22 non-MI CCH patients (30 injections) and 50 ECH patients (63 injections). Nineteen MICCH patients received repeated injections (32 in total,...Show moreIntroduction Current prophylactic drugs for cluster headache are associated with limited efficacy, serious side effects and poor tolerability. Greater occipital nerve injection (GON-injection) has been proven effective and safe as a single, one-time injection in episodic (ECH), and to a lesser extent, chronic cluster headache (CCH). We aim to analyse the effectiveness and safety of repeated GON-injections in medically intractable chronic cluster headache (MICCH). Methods Clinical data of all cluster headache patients who had received at least one GON-injection between 2014 and 2018 in our tertiary headache centre were retrieved from patients' medical records. Clinical history was taken as part of routine care shortly before and 6 weeks after GON-injection. Results We identified 47 MICCH patients (79 injections), and compared results with 22 non-MI CCH patients (30 injections) and 50 ECH patients (63 injections). Nineteen MICCH patients received repeated injections (32 in total, range 2-8). Rates of clinical relevant improvement to a first injection were similar in all groups (MICCH: 60%, non-MICCH 73%, ECH 76%; attack freedom: MICCH: 30%, non-MICCH 32%, ECH 43%). Furthermore, no difference in response to the first and second injection was shown between groups (all p > 0.29). Median effect duration in MICCH was 6 weeks (IQR 2.8-12 weeks). Side effects were only mild and local. Conclusion In this retrospective analysis, first and repeated GON-injections were well-tolerated and equally effective in MICCH as in non-MICCH, and ECH.Show less
Neuromodulation
Prophylactic treatment
Pain
Nerve block
All authors
Brandt, R.B.; Doesborg, P.G.G.; Meilof, R.; Coo, I.F. de; Bartels, E.; Ferrari, M.D.; Fronczek, R.
Date
2021-06-22
Journal
Neurological Sciences
Volume
43
Pages
1267 - 1272
DOI
doi:10.1007/s10072-021-05399-5
Link
https://link.springer.com/content/pdf/10.1007/s10072-021-05399-5.pdf